Literature DB >> 16822084

Pediatric undifferentiated sarcoma of the soft tissues: a clinicopathologic study.

Gino R Somers1, Abha A Gupta, Andrea S Doria, Michael Ho, Carlos Pereira, Mary Shago, Paul S Thorner, Maria Zielenska.   

Abstract

Pediatric undifferentiated soft tissue sarcomas represent a major challenge for pathologists and clinicians. The goal of this study was to identify cases that warranted this diagnosis by current standards of analysis and then determine if there are clinicopathological commonalities that may be useful for diagnosis, management, and prognosis. Eighteen potential patients were identified using the institutional pathology database. Three cases were reclassified as specific sarcomas, and 2 cases had insufficient material for molecular analysis, leaving 13 cases for pathological review and 12 patients for radiological and clinical review. There were 7 males and 6 females. The median age at diagnosis was 11 years (1 month to 16 years). Tumors commonly involved the trunk (7 of 13; 54%) and ranged in size from 1.7 to 14.5 cm (mean, 6.7 cm). Eleven patients received ifosfamide/etoposide chemotherapy and 4 received irradiation. Five-year event-free and overall survival (EFS and OS) rates were 54% and 74%, respectively. The predominant histological pattern was round to plump spindled cells forming sheets (9 of 13; 69%) and severe atypia was associated with decreased survival (P = 0.048). Immunohistochemistry showed positivity for vimentin (92%), CD117 (92%), and vascular endothelial growth factor (69%), and 8% to 23% showed focal positivity for epithelial, neural, or myogenic markers. Tumors were uniformly negative for translocations associated with pediatric sarcomas. The presence of certain common morphological and immunohistochemical features in the absence of specific molecular genetic abnormalities allows for a diagnosis of pediatric undifferentiated soft tissue sarcoma; however, whether this group of neoplasms forms a unique category of tumors or a common precursor pathway for a number of different sarcomas awaits further study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822084     DOI: 10.2350/08-05-0098.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  12 in total

1.  Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.

Authors:  Lorena Lazo de la Vega; Daniel H Hovelson; Andi K Cani; Chia-Jen Liu; Jonathan B McHugh; David R Lucas; Dafydd G Thomas; Rajiv M Patel; Scott A Tomlins
Journal:  Hum Pathol       Date:  2016-09-21       Impact factor: 3.466

2.  Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.

Authors:  Chao Lu; Siddhant U Jain; Dominik Hoelper; Denise Bechet; Rosalynn C Molden; Leili Ran; Devan Murphy; Sriram Venneti; Meera Hameed; Bruce R Pawel; Jay S Wunder; Brendan C Dickson; Stefan M Lundgren; Krupa S Jani; Nicolas De Jay; Simon Papillon-Cavanagh; Irene L Andrulis; Sarah L Sawyer; David Grynspan; Robert E Turcotte; Javad Nadaf; Somayyeh Fahiminiyah; Tom W Muir; Jacek Majewski; Craig B Thompson; Ping Chi; Benjamin A Garcia; C David Allis; Nada Jabado; Peter W Lewis
Journal:  Science       Date:  2016-05-13       Impact factor: 47.728

3.  Undifferentiated and Unresectable Sarcoma With NTRK3-Fusion in a Pediatric Patient Treated With Larotrectinib and Proton Beam Radiotherapy.

Authors:  Mallery R Olsen; Ryan A Denu; Jane B Lyon; Jessica M Gulliver; Christian M Capitini; Kenneth B DeSantes
Journal:  J Pediatr Hematol Oncol       Date:  2022-04-01       Impact factor: 1.289

4.  Superficial EWSR1-negative undifferentiated small round cell sarcoma with CIC/DUX4 gene fusion: a new variant of Ewing-like tumors with locoregional lymph node metastasis.

Authors:  Isidro Machado; Julia Cruz; Javier Lavernia; Luis Rubio; Jorge Campos; María Barrios; Camille Grison; Virginie Chene; Gaelle Pierron; Olivier Delattre; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2013-11-10       Impact factor: 4.064

Review 5.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

6.  Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas.

Authors:  Portia A Kreiger; Alexander R Judkins; Pierre A Russo; Jaclyn A Biegel; Brian J Lestini; Chatchawin Assanasen; Bruce R Pawel
Journal:  Mod Pathol       Date:  2008-11-07       Impact factor: 7.842

7.  Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics.

Authors:  Yin P Hung; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

8.  JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma.

Authors:  Adam D Durbin; Gino R Somers; Michael Forrester; Malgorzata Pienkowska; Gregory E Hannigan; David Malkin
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

Review 9.  Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.

Authors:  Frank Peinemann; Lesley A Smith; Carmen Bartel
Journal:  Cochrane Database Syst Rev       Date:  2013-08-07

10.  Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group.

Authors:  Theodore W Laetsch; Angshumoy Roy; Lin Xu; Jennifer O Black; Cheryl M Coffin; Yueh-Yun Chi; Jing Tian; Sheri L Spunt; Douglas S Hawkins; Julia A Bridge; D Williams Parsons; Stephen X Skapek
Journal:  Clin Cancer Res       Date:  2018-04-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.